SG11201703826TA - Formulations of a pi3k/mtor-inhibitor for intravenous administration - Google Patents

Formulations of a pi3k/mtor-inhibitor for intravenous administration

Info

Publication number
SG11201703826TA
SG11201703826TA SG11201703826TA SG11201703826TA SG11201703826TA SG 11201703826T A SG11201703826T A SG 11201703826TA SG 11201703826T A SG11201703826T A SG 11201703826TA SG 11201703826T A SG11201703826T A SG 11201703826TA SG 11201703826T A SG11201703826T A SG 11201703826TA
Authority
SG
Singapore
Prior art keywords
pi3k
mtor
formulations
inhibitor
intravenous administration
Prior art date
Application number
SG11201703826TA
Other languages
English (en)
Inventor
Kevin Richard Back
Michael Cram
Aidan James Harper
W James Huang
Jonathan Richard Lillis
Timothy Michael Lukas
Sumit Luthra
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SG11201703826TA publication Critical patent/SG11201703826TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201703826TA 2014-12-17 2015-12-10 Formulations of a pi3k/mtor-inhibitor for intravenous administration SG11201703826TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462093060P 2014-12-17 2014-12-17
US201562250633P 2015-11-04 2015-11-04
PCT/IB2015/059515 WO2016097949A1 (en) 2014-12-17 2015-12-10 Formulations of a pi3k/mtor-inhibitor for intravenous administration

Publications (1)

Publication Number Publication Date
SG11201703826TA true SG11201703826TA (en) 2017-07-28

Family

ID=54937330

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201703826TA SG11201703826TA (en) 2014-12-17 2015-12-10 Formulations of a pi3k/mtor-inhibitor for intravenous administration

Country Status (25)

Country Link
US (2) US10172942B2 (cg-RX-API-DMAC7.html)
EP (1) EP3233054B1 (cg-RX-API-DMAC7.html)
JP (1) JP6420753B2 (cg-RX-API-DMAC7.html)
KR (1) KR102016822B1 (cg-RX-API-DMAC7.html)
CN (1) CN107205923B (cg-RX-API-DMAC7.html)
AU (1) AU2015365497B2 (cg-RX-API-DMAC7.html)
CA (1) CA2915199C (cg-RX-API-DMAC7.html)
CY (1) CY1124527T1 (cg-RX-API-DMAC7.html)
DK (1) DK3233054T3 (cg-RX-API-DMAC7.html)
ES (1) ES2881214T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211446T1 (cg-RX-API-DMAC7.html)
HU (1) HUE055928T2 (cg-RX-API-DMAC7.html)
IL (1) IL252158B (cg-RX-API-DMAC7.html)
LT (1) LT3233054T (cg-RX-API-DMAC7.html)
MX (1) MX380172B (cg-RX-API-DMAC7.html)
NZ (1) NZ731518A (cg-RX-API-DMAC7.html)
PL (1) PL3233054T3 (cg-RX-API-DMAC7.html)
PT (1) PT3233054T (cg-RX-API-DMAC7.html)
RS (1) RS62337B1 (cg-RX-API-DMAC7.html)
RU (1) RU2672875C1 (cg-RX-API-DMAC7.html)
SG (1) SG11201703826TA (cg-RX-API-DMAC7.html)
SI (1) SI3233054T1 (cg-RX-API-DMAC7.html)
TW (1) TWI660729B (cg-RX-API-DMAC7.html)
WO (1) WO2016097949A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201703764B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3672571T (lt) 2017-08-25 2021-12-10 Pfizer Inc. Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidą
US12109308B2 (en) * 2018-06-07 2024-10-08 Pfizer Inc. Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yljcarbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
KR20240040768A (ko) 2021-07-26 2024-03-28 셀퀴티 인크. 암의 치료에 사용하기 위한 1-(4-{[4-(디메틸아미노)피페리딘-1-일]카르보닐}페닐)-3-[4-(4,6-디모르폴린-4-일-1,3,5-트리아진-2-일)페닐]우레아 (게다톨리십) 및 그의 조합물
WO2025128712A1 (en) 2023-12-12 2025-06-19 Celcuity Inc. Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl)phenyl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phenyl]urea
US20260053814A1 (en) 2024-08-21 2026-02-26 Celcuity Inc. Treatment regimens for gedatolisib in hormonally-driven disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
AU2006251429A1 (en) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Combination therapy comprising a diaryl urea compound and a PI3, AKT kinase or mTOR inhibitors (rapamycins) for cancer treatment
US20080234262A1 (en) * 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
DE202008001253U1 (de) * 2008-01-28 2008-04-10 Mirror Image Ag Bildanzeigegerät
MY155653A (en) 2008-05-23 2015-11-13 Wyeth Llc Triazine compounds as p13 kinase and mtor inhibitors
ES2533788T3 (es) * 2008-05-30 2015-04-14 Genentech, Inc. Compuestos inhibidores de PI3K de tipo purina y métodos de uso
WO2010096619A1 (en) * 2009-02-23 2010-08-26 Wyeth Llc Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
US9757432B2 (en) * 2012-11-14 2017-09-12 Ohio State Innovation Foundation Materials and methods useful for treating glioblastorna
JP6309610B2 (ja) * 2013-03-14 2018-04-11 アブラクシス バイオサイエンス, エルエルシー 膀胱がんを処置する方法
EP3116547B1 (en) * 2014-03-14 2019-06-05 Pfizer Inc Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same

Also Published As

Publication number Publication date
RU2672875C1 (ru) 2018-11-20
JP6420753B2 (ja) 2018-11-07
RS62337B1 (sr) 2021-10-29
US20190105390A1 (en) 2019-04-11
MX380172B (es) 2025-03-12
SI3233054T1 (sl) 2021-11-30
HRP20211446T1 (hr) 2021-12-24
US20170360935A1 (en) 2017-12-21
JP2016113461A (ja) 2016-06-23
DK3233054T3 (da) 2021-08-02
PT3233054T (pt) 2021-08-02
AU2015365497A1 (en) 2017-06-01
TW201632188A (zh) 2016-09-16
WO2016097949A1 (en) 2016-06-23
BR112017010841A2 (pt) 2017-12-26
AU2015365497B2 (en) 2020-07-02
PL3233054T3 (pl) 2021-12-20
HUE055928T2 (hu) 2022-01-28
KR102016822B1 (ko) 2019-08-30
EP3233054A1 (en) 2017-10-25
LT3233054T (lt) 2021-07-26
CA2915199C (en) 2018-11-06
CY1124527T1 (el) 2022-07-22
KR20170082638A (ko) 2017-07-14
US10172942B2 (en) 2019-01-08
CN107205923B (zh) 2021-03-05
US10660959B2 (en) 2020-05-26
EP3233054B1 (en) 2021-06-30
IL252158A0 (en) 2017-07-31
CN107205923A (zh) 2017-09-26
MX2017008072A (es) 2017-09-28
NZ731518A (en) 2019-03-29
CA2915199A1 (en) 2016-06-17
TWI660729B (zh) 2019-06-01
ZA201703764B (en) 2020-11-25
ES2881214T3 (es) 2021-11-29
IL252158B (en) 2021-01-31

Similar Documents

Publication Publication Date Title
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
IL278034B (en) Proton binding polymers for oral administration
IL251726A0 (en) Viscosity reduction of pharmaceutical preparations
PT3237045T (pt) Dispositivo para administração de produtos medicinais
PL3191167T3 (pl) Zawór do podawania płynnych leków
ZA201605263B (en) Pharmaceutical composition for topical administration
ZA201401683B (en) Pharmaceutical compositions for rectal administration
EP3256133A4 (en) Intravenous infusion dosage form
PL3191168T3 (pl) Zawór do podawania wielu płynów leczniczych
IL255853B (en) Nano-particles for use as a therapeutic vaccine
ZA201608785B (en) Nasal administration
ZA201703562B (en) Pharmaceutical composition for oral administration comprising taxane
LT3226888T (lt) Selektyvaus il-6-trans-signalinio inhibitoriaus skyrimas
ZA201703764B (en) Formulations of a pi3k/mtor-inhibitor for intravenous administration
HRP20181968T1 (hr) Formulacije temeljene na melatoninu za parenteralno davanje
GB201419540D0 (en) Delivery of drugs
EP3355888B8 (en) Hemi-synthetic trilobine analogs for use as a drug
GB201417589D0 (en) Pharmaceutical Formulations
PH32014000630S1 (en) Syringe for oral medication
HK1229386A1 (en) Administration regime
GB201403532D0 (en) Intravenous cannula
GB201407741D0 (en) Novel drug formulation
ZA201405476B (en) Anthelmintic medicament
GB201400951D0 (en) Novel drug formulation